Literature DB >> 22203769

Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.

Michela Maur1, Chiara Tomasello, Antonio Frassoldati, Maria Vittoria Dieci, Elena Barbieri, Pierfranco Conte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203769     DOI： 10.1200/JCO.2011.38.7886

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  38 in total

Review 1.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

Review 2.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

3.  Primary brain tumors and posterior reversible encephalopathy syndrome.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Adriana Olar; Terri S Armstrong; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2014-09-14

4.  Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.

Authors:  Samuel Singer; Christian Grommes; Anne S Reiner; Marc K Rosenblum; Lisa M DeAngelis
Journal:  Oncologist       Date:  2015-06-01

5.  [Treatment side effects and follow-up of malignant melanoma].

Authors:  T Stahl; C Loquai
Journal:  Radiologe       Date:  2015-02       Impact factor: 0.635

Review 6.  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.

Authors:  Lisa A Kottschade
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

Review 7.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

Review 8.  Immune-related Adverse Events in Cancer Patients.

Authors:  Daniel J Pallin; Christopher W Baugh; Michael A Postow; Jeffrey M Caterino; Timothy B Erickson; Gary H Lyman
Journal:  Acad Emerg Med       Date:  2018-05-25       Impact factor: 3.451

Review 9.  Toxicities of Immunotherapy for the Practitioner.

Authors:  Jeffrey S Weber; James C Yang; Michael B Atkins; Mary L Disis
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 10.  Toxicity management of immunotherapy for patients with metastatic melanoma.

Authors:  Helena Linardou; Helen Gogas
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.